These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 25036111

  • 41. Exploring the drug resistance of V32I and M46L mutant HIV-1 protease to inhibitor TMC114: flap dynamics and binding mechanism.
    Meher BR, Wang Y.
    J Mol Graph Model; 2015 Mar; 56():60-73. PubMed ID: 25562662
    [Abstract] [Full Text] [Related]

  • 42. Rapid and accurate prediction of binding free energies for saquinavir-bound HIV-1 proteases.
    Stoica I, Sadiq SK, Coveney PV.
    J Am Chem Soc; 2008 Feb 27; 130(8):2639-48. PubMed ID: 18225901
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
    Kozísek M, Bray J, Rezácová P, Sasková K, Brynda J, Pokorná J, Mammano F, Rulísek L, Konvalinka J.
    J Mol Biol; 2007 Dec 07; 374(4):1005-16. PubMed ID: 17977555
    [Abstract] [Full Text] [Related]

  • 47. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.
    Hou T, Yu R.
    J Med Chem; 2007 Mar 22; 50(6):1177-88. PubMed ID: 17300185
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Exploring the drug resistance mechanism of active site, non-active site mutations and their cooperative effects in CRF01_AE HIV-1 protease: molecular dynamics simulations and free energy calculations.
    C S V, Tamizhselvi R, Munusami P.
    J Biomol Struct Dyn; 2019 Jul 22; 37(10):2608-2626. PubMed ID: 30051758
    [Abstract] [Full Text] [Related]

  • 50. Computational simulations of HIV-1 proteases--multi-drug resistance due to nonactive site mutation L90M.
    Ode H, Neya S, Hata M, Sugiura W, Hoshino T.
    J Am Chem Soc; 2006 Jun 21; 128(24):7887-95. PubMed ID: 16771502
    [Abstract] [Full Text] [Related]

  • 51. Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir.
    Prashar V, Bihani SC, Ferrer JL, Hosur MV.
    Chem Biol Drug Des; 2015 Sep 21; 86(3):302-8. PubMed ID: 25487655
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs.
    Nillroth U, Vrang L, Markgren PO, Hultén J, Hallberg A, Danielson UH.
    Antimicrob Agents Chemother; 1997 Nov 21; 41(11):2383-8. PubMed ID: 9371337
    [Abstract] [Full Text] [Related]

  • 54. Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir.
    Markland W, Rao BG, Parsons JD, Black J, Zuchowski L, Tisdale M, Tung R.
    J Virol; 2000 Aug 21; 74(16):7636-41. PubMed ID: 10906218
    [Abstract] [Full Text] [Related]

  • 55. Drug Resistance Mechanism of L10F, L10F/N88S and L90M mutations in CRF01_AE HIV-1 protease: Molecular dynamics simulations and binding free energy calculations.
    Vasavi CS, Tamizhselvi R, Munusami P.
    J Mol Graph Model; 2017 Aug 21; 75():390-402. PubMed ID: 28645089
    [Abstract] [Full Text] [Related]

  • 56. Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo.
    Ermolieff J, Lin X, Tang J.
    Biochemistry; 1997 Oct 07; 36(40):12364-70. PubMed ID: 9315877
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Proteochemometric modeling of drug resistance over the mutational space for multiple HIV protease variants and multiple protease inhibitors.
    Lapins M, Wikberg JE.
    J Chem Inf Model; 2009 May 07; 49(5):1202-10. PubMed ID: 19391634
    [Abstract] [Full Text] [Related]

  • 59. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.
    Ananworanich J, Hirschel B, Sirivichayakul S, Ubolyam S, Jupimai T, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Schutz M, Snowden W, Ruxrungtham K, Staccato Study Team.
    Antivir Ther; 2006 May 07; 11(5):631-5. PubMed ID: 16964832
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.